Skip to main content

Table 1 Test performance and Disease prevalence estimates

From: Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease

Test characteristics Sensitivity Specificity Reference
Standard of care 0.35 0.65 Expert Opinion [16, 17]
FIB-4 (cut off 1.30) 0.84 0.74 [18, 19]
FIB-4 (cut off 3.25) 0.38 0.97 [18, 19]
ELF 0.80 0.90 [19, 20]
Fibroscan 0.82 0.84 [19, 21]
Population and disease characteristics Transition probability  
Prevalence of advanced fibrosis in the general population 0.075 [5]
  1. Published test characteristics of non-invasive liver fibrosis tests to detect advanced fibrosis (METAVIR ≥F3) in patients with non-alcoholic fatty liver disease